• Time of survival time for patients treated with imatinib with or without chemotherapy is between 7 and 11 months, and the rate of total remission is between 12 and 20 percent.
  • Remission rates appear to be higher when patients receive dasatinib, nilotinib or ponatinib, with 30-50% entered into remission.
  • This is why allogeneic transplantation should be considered as soon as possible in patients for whom this is the only possibility to cure the disease if they are candidates for this procedure, evaluating this option while the patient is in the most optimal state possible following initial treatment with chemotherapy and a tyrosine kinase inhibitor.